Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) unresectable or metastatic colorectal cancer (SMC2820)

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Nivolumab in combination with ipilimumab for the first-line treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) unresectable or metastatic colorectal cancer (SMC2820) is being assessed for use by NHSScotland.

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of systemic anti-cancer therapy (SACT) for the first-line treatment of adults with dMMR or MSI-H unresectable or metastatic colorectal cancer. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2820, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients receiving first-line SACT for the treatment of dMMR or MSI-H unresectable or metastatic colorectal cancer.
• Describe the baseline characteristics and treatment pathways of patients receiving first-line SACT for treatment of dMMR or MSI-H unresectable or metastatic colorectal cancer.